LifeMax Receives Orphan Drug Designation From the United States Food & Drug Administration For LM-030 For The Treatment of Netherton Syndrome
Palo Alto, California – (Business Wire) – June 27, 2019 – LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the Food & Drug Administration (FDA) granted orphan drug designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into pivotal clinical trials for the treatment of Netherton Syndrome.
“We are very pleased to have received the orphan drug designation for LM-030 which has demonstrated safety and clinical efficacy in a Phase I/II study. Netherton Syndrome is a severe genetic disorder with neonate onset that can be life-threatening. Receiving the orphan drug designation represents a significant step in the development of LM-030 for this devastating disease,” said Larry Hsu, LifeMax’s Co-founder and CEO, an industry veteran who previously founded and built Impax Laboratories into a publicly traded multi-billion dollar company.
Orphan drug designation is granted by the FDA Office of Orphan Products Development to promote the development of investigational therapies for diseases affecting less than 200,000 people in the US. Benefits that come with an orphan drug designation include, but not limited to, tax credits for clinical development cost and seven-year market exclusivity.
About Netherton Syndrome
Netherton Syndrome is a severe autosomal recessive disease characterized by congenital erythroderma, “bamboo hair” and abnormality in the immune system. It can be life-threatening in pediatrics due to impaired skin barrier that leads to severe dehydration, hypernatremia, hypothermia, gross weight loss and sepsis. Failure to thrive is common in childhood as a result of chronic erythroderma, persistent cutaneous infection, malnutrition and metabolic disorders. The severity of the skin abnormality in older patients can fluctuate over time. Most Netherton Syndrome patients are also inflicted with immune system-related disorders such as food allergies and asthma.
Though the exact prevalence of Netherton Syndrome is not well documented, it has a reported prevalence of 1-9 per 1,000,000.
About LifeMax Laboratories Inc.
LifeMax Laboratories, Inc. (www.lifemaxlabs.com), a wholly-owned subsidiary of LifeMax Healthcare International Corporation (www.lifemaxhealthcare.com), is a clinical-stage biotech company focused on treating rare diseases with few or no therapeutic options. LifeMax is applying its expertise and in-depth experience with drug development and commercialization to advance its well-balanced portfolio of products addressing critical unmet medical needs.
Media Contact
LifeMax Laboratories, Inc.
Laura Zhu, Ph.D., MBA
Tel: 650-285-6560 ext. 103
To view the original version on Business Wire, please visit
